ArticleClinical kidney journal2021

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.

Christoph Wanner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.